Top Research Reports for AMD, Linde & Amgen

Friday, September 18, 2026

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Advanced Micro Devices, Inc. (AMD), Linde plc (LIN) and Amgen Inc. (AMGN), as well as a micro-cap stock INNOVATE Corp. (VATE). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> End of an Era: The Oracle of Omaha Steps Down

Today's Featured Research Reports

AMD’s shares have outperformed the Zacks Computer - Integrated Systems industry over the year-to-date period (+154.6% vs. +117.1%). The company is benefiting from broadening AI infrastructure demand as EPYC server CPUs and Instinct accelerators gain traction across cloud and enterprise customers. Helios is beginning its production ramp, while multigigawatt commitments from leading model developers improve visibility into AI deployments. 

Venice strengthens the server roadmap, and management expects server growth to remain elevated into 2027. Client share gains and an Embedded recovery add diversification. 

However, tight supply across wafers, packaging, memory and rack components raises execution risk as Helios scales. Data center AI mix can constrain gross-margin expansion, while softer PC and gaming demand and customer concentration temper the upside. Overall, AMD’s broader platform opportunity is balanced by execution and margin risks, supporting a Neutral view.

(You can read the full research report on AMD here >>>)

Shares of Linde have outperformed the Zacks Chemical - Specialty industry over the year-to-date period (+8.6% vs. +5.9%). The company combines a resilient business model with long-term customer contracts, diversified industrial gas end markets and a sizable project backlog that supports cash flow visibility. Its backlog is supported by long-term supply agreements and a healthy project pipeline. 

Electronics remains its fastest-growing end market, with AI-linked semiconductor demand and new U.S. and Taiwan investments supporting growth. Pricing, productivity and project start-ups support earnings. 

However, industrial demand remains uneven across regions. EMEA volumes are soft, while Middle East disruptions affect parts of Asia. U.S. homecare and lower-margin APAC equipment sales are weighing on margins. Foreign exchange adds variability. The Neutral view balances contracted growth and semiconductor exposure with regional demand, margin and currency risks.

(You can read the full research report on Linde here >>>)

Amgen’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+18.4% vs. +8.7%). The company markets a range of drugs across oncology, cardiovascular, bone health, immunology and other areas. Amgen’s key medicines like Evenity, Repatha and Uplizna, as well as newer medicines like Imdelltra, Tavneos and Tezspire, are driving sales, more than offsetting declining revenues from oncology biosimilars and mature products like Enbrel. 

New biosimilar launches are also contributing to top-line growth. Furthermore, Amgen has several key pipeline assets, with a primary focus on the obesity candidate, MariTide. 

However, price declines and increased competition are hurting sales of some products. Sales of best-selling drugs, Prolia and Xgeva, are declining sharply in 2026 due to biosimilar launches. Recent pipeline setbacks and the upcoming LOE cliff are concerns. 

(You can read the full research report on Amgen here >>>)

Shares of INNOVATE have outperformed the Zacks Diversified Operations industry over the year-to-date period (+73.9% vs. -1.2%). This microcap company with a market capitalization of $107.22 million benefits from strong infrastructure demand, a sizable backlog and improving execution at DBMG, which support multi-year revenue visibility and margin resilience. Exposure to data centers, AI infrastructure, healthcare and advanced manufacturing provides additional growth avenues. 

MediBeacon’s commercialization progress and R2’s international expansion offer longer-term optionality, while the Broadcasting transaction could simplify the balance sheet and preserve participation in future upside. 

However, INNOVATE’s leveraged capital structure, sizable near-term maturities and weak parent-level liquidity remain key concerns. Dependence on DBMG for earnings and cash support heightens the impact of its required sale, while capitalized interest and limited cash conversion constrain deleveraging.

(You can read the full research report on INNOVATE here >>>)

Other noteworthy reports we are featuring today include Phillips 66 (PSX), Johnson Controls International plc (JCI) and Aon plc (AON).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Strong Product Portfolio & Strong Clientele Aid AMD's Prospects

Linde's (LIN) Long-Term Contracts With Minimum Volume Commitments Aid

Amgen (AMGN) Key & New Drugs Driving Sales Amid LOE Concerns

Featured Reports

HVAC & Controls Aids Johnson Controls (JCI) Amid Forex Woes
Per the Zacks analyst, continued demand for HVAC & Controls within the Americas segment is likely to drive Johnson Controls' revenues. However, forex woes remain a concern for the company.

Aon's (AON) Strategic Acquisitions Aid, Expenses Woes Linger
Per the Zacks analyst, several acquisitions and collaborations are helping AON enhance its capabilities and driving its profit growth. However, rising expenses remain a concern.

Defense Demand Aids Rocket Lab Amid Neutron Risks (RKLB)
Per the Zacks analyst, Rocket Lab benefits from rising defense demand and record contract wins, while Neutron development and launch execution risks temper the outlook.

Focus on Alternatives, Solid Liquidity Aid Affiliated Managers (AMG)
Per the Zacks analyst, Affiliated Managers is well-placed for growth, driven by its focus on alternatives strategies, successful partnerships, global distribution capability and a solid balance sheet.

Lumen Gains from AI Momentum, but Legacy & Debt Pressures Concerns
Per the Zacks analyst, Lumen's $13B PCF deals, rising strategic revenue mix and NaaS adoption support its AI-led shift, while legacy declines and heavy debt keep the growth outlook balanced.

WGNSTAR Buyout Supports ABM Growth Amid Weakness in Office Markets
Per the Zacks analyst, the WGNSTAR acquisition expands ABM's semiconductor capabilities. Meanwhile, persistent weakness in office markets could constrain growth and profitability.

New Business Wins, Transformation Savings Aid Quaker Chemical (KWR)
Per the Zacks analyst, the company will continue to benefit from share gains across regions driven by new business wins. Savings from transformation actions will also support margins.

New Upgrades

Diversified Assets & Commercial Flexibility to Aid Phillips 66 (PSX)
Per the Zacks analyst, PSX's diversified portfolio, commercial flexibility, midstream growth, disciplined capital allocation & deleveraging support cash generation amid volatility & global demand.

Five Below (FIVE) Gains on Higher Traffic, Strong Comps Growth
Per the Zacks analyst, Five Below gains from higher transactions, better conversion, and increased customer traffic, which drove comps in Q2. The company expects third quarter comps growth of 8-10%.

Engagement-Led Growth & New Products Aid Sezzle (SEZL) Profitability
Per the Zacks analyst, Sezzle benefits from rising subscriber activity, purchase frequency and efficient customer acquisition. New products, lower funding costs and AI-led operations support growth.

New Downgrades

Weak Revenue Growth and Rising AI Costs Hurt Dropbox (DBX) Prospects
Per the Zacks analyst, weak revenue growth, ARPU pressure, rising AI costs and stiff competition are expected to hurt Dropbox's prospects.

Reimbursement Friction Irks Myriad's Sales Amid Unfavorable FX
The Zacks Analyst worries that reimbursement friction and collection difficulties may pressure Myriad's growth and margin recovery. Unfavorable foreign exchange may also hurt growth.

Weak Housing Market & Pricing Pressure Hurt KB Home's (KBH) Prospects
Per the Zacks analyst, KB Home faces affordability constraints, elevated mortgage rates and pricing pressure. Also, lower delivery and housing revenue expectations remain concerns.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research